PROSTALUND AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.075 SEK | -0.46% |
|
+10.14% | -34.05% |
| 08/04 | ProstaLund AB Presents Two New Studies with Schelin Catheter | CI |
| 16/02 | ProstaLund AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2021 | 17.07M 1.58M 132M | Sales 2022 | 17.41M 1.62M 135M | Capitalization | 228M 21.21M 1.77B |
|---|---|---|---|---|---|
| Net income 2021 | -7M -650K -54.22M | Net income 2022 | -11M -1.02M -85.2M | EV / Sales 2021 | 11.7 x |
| Net cash position 2021 | 13.04M 1.21M 101M | Net cash position 2022 | 10.54M 979K 81.65M | EV / Sales 2022 | 12.5 x |
| P/E ratio 2021 |
-24.4
x | P/E ratio 2022 |
-19
x | Employees | 7 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 47.95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.46% | ||
| 1 week | +10.14% | ||
| Current month | +9.92% | ||
| 1 month | -0.92% | ||
| 3 months | -30.42% | ||
| 6 months | -50.91% | ||
| Current year | -34.05% |
1 week
0.96
1.10
1 month
0.911.20
Current year
0.911.90
1 year
0.914.01
3 years
0.916.72
5 years
0.917.94
10 years
0.9125.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/23/01 | |
Niclas Nyström
DFI | Director of Finance/CFO | 59 | 06/12 |
Johan Laven
SAM | Sales & Marketing | 51 | 01/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul de Potocki
BRD | Director/Board Member | 62 | 12/23/12 |
| Director/Board Member | 59 | 01/23/01 | |
| Director/Board Member | 60 | 12/23/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/24/06 | 1.075 | -0.46% | 81 538 |
| 03/24/03 | 1.08 | +10.20% | 240,275 |
| 02/24/02 | 0.98 | +0.20% | 16,620 |
| 30/24/30 | 0.978 | +0.20% | 14,899 |
| 29/24/29 | 0.976 | +2.74% | 58,460 |
Delayed Quote Nasdaq Stockholm, May 06, 2024 at 06:41 pm IST
More quotes
ProstaLund AB is a Sweden-based company that provides health care products and services. The Company develops and manufactures urological devices and treatments primarily for benign prostatic hyperplasia (BPH). The Company develops CoreTherm, a patented Thermotherapy treatment method for BPH, which takes approximately 6-15 minutes and offers long-term symptom relief. CoreTherm is used in hospitals and clinics in Sweden and worldwide.
Calendar
16/05/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -34.05% | 7.66M | |
| -3.94% | 184B | |
| -0.94% | 108B | |
| -2.79% | 67.82B | |
| +4.28% | 51.05B | |
| +9.12% | 44.67B | |
| +3.40% | 41.78B | |
| +1.87% | 26.78B | |
| +4.14% | 26.59B | |
| +15.23% | 25.86B |
- Stock Market
- Equities
- PLUN Stock